Project Grant R03CA299359
- Federal Project Grant Award Summary Wayne State University received a $183,309 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) effective August 1, 2025, through July 31, 2030. The grant supports a research investigation examining socio-genomic associations related to survival outcomes among women diagnosed with endometrial cancer in the Detroit metropolitan area. The project aims to understand why certain high-risk populations...
- Federal Grant Award Summary New York University received a $442,750 Project Grant from the National Cancer Institute (National Institutes of Health) under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded on September 23, 2025, with completion targeted for August 31, 2027. This research project delivers a systematic, theory-based analysis of cervical cancer control policy implementation in African low- and middle-income countries through three primary research activities:...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Wayne State University $371,024 under the Cancer Biology Research program (CFDA 93.396) on April 1, 2026, to support a five-year project through March 31, 2031. This project grant funds fundamental research investigating the essential roles of noncanonical signaling pathways of Janus Kinases 1 and 2 (JAK1 and JAK2) in mammary gland development and breast cancer. The research will employ genetically engineered mouse models to...
- Federal Grant Award Summary The National Cancer Institute awarded a $498,565 Project Grant to The University of Texas MD Anderson Cancer Center on September 8, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop a Globally Accessible and Pragmatic Predictive Signature (GAPPS) for locally advanced cervical cancer. The project, extending through July 31, 2029, aims to create response-based biomarkers—including imaging techniques and blood biomarkers—to enable risk...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $627,148 to the University of Maryland, College Park on August 5, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an image-guided ethyl cellulose ethanol ablation therapy for treating cervical dysplasia in low and middle-income countries (LMICs). The project, extending through July 31, 2030, builds upon prior Small Business Innovation Research (SBIR) funding...
- Federal Project Grant Award Summary The National Cancer Institute awarded the University of Michigan a $682,272 Project Grant effective September 1, 2025, through August 31, 2027, under the Cancer Cause and Prevention Research program (CFDA 93.393) to assess the feasibility and acceptability of a multifaceted electronic health record (EHR)-integrated mobile health intervention designed to reduce hospital readmissions following radical cystectomy in bladder cancer patients. The intervention...
- Federal Grant Award Summary Tufts Medical Center Parent, Inc. received a $3.28 million Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded on August 15, 2025, with performance extending through July 31, 2029. The grant funds development and deployment of English and Spanish-language Embodied Conversational Agents (ECAs) for cervical cancer screening abnormalities follow-up (ECA-CCSA). The smartphone-based ECAs will...
- Federal Grant Award Summary Michigan State University (through its Henry Ford Health+Michigan State University Health Sciences partnership) received a $153,278 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) effective July 3, 2025, with completion expected June 30, 2027. The award supports the development of a Dre-Rox recombination-based Genetically Engineered Mouse Model (GEMM) for NUT carcinoma, a rare but aggressive...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Oklahoma Health Sciences Center a Project Grant of $376,490 under the Cancer Treatment Research program (CFDA 93.395) beginning July 1, 2025 and concluding June 30, 2027. This award supports research and development of a novel therapeutic combination strategy targeting cervical cancer through the integration of a C-MYC inhibitor (MYCI975) with SHETA2, an investigational heat shock protein inhibitor...
- Federal Project Grant Award Summary The National Cancer Institute awarded $544,250 to the University of Nebraska Medical Center (UNMC) under the Cancer Treatment Research program (CFDA 93.395) for a five-year project running from August 4, 2025 through July 31, 2030. The award supports research investigating the immune drivers of persistent oncogenic human papillomavirus (HPV) infections in people living with HIV (PLWH), with an initial focus on oral HPV persistence as a precursor to...
Wayne State University received a $155,000 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) effective May 1, 2026, through April 30, 2028. This research initiative addresses a critical gap in cervical cancer (CC) prevention by investigating multi-level predictors of diagnostic follow-up (DFU) attendance after abnormal cervical cancer screening. While the United States has made progress toward Human Papillomavirus (HPV) vaccination and screening goals, DFU completion rates remain significantly below the 90% target necessary for cervical cancer elimination, with only 25-80% of women with abnormal screens completing diagnostic follow-up. The project will identify individual-level and clinic-level barriers and facilitators to DFU completion to inform the development of future interventions designed to improve cervical cancer screening outcomes and reduce preventable cases and deaths in the U.S. population. The research addresses a substantial public health need, as cervical cancer incidence in the United States remains nearly double the elimination threshold of 4 per 100,000 women, resulting in approximately 14,000 new cases and 4,500 preventable deaths annually. By systematically examining associations between screening barriers, clinic-level facilitators, and DFU completion through multi-level analysis, this project will generate evidence to support the development of targeted interventions that enhance the final pillar of the World Health Organization's cervical cancer elimination strategy and improve health outcomes across diverse populations.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $155.0k | 4/13/26 |